explore -WSS

explore

author：hotspot 2025-10-01 10:58:20 - browse：81648

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Shingles, which affected Dianne Feinstein, is on the rise

WSS

Couple fighting to bring baby home from Mexico are finally reunited

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Menendez indictment could see pharma lose a key ally

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

After a drawn out lobbying fight, ARPA

How dance can help health care workers heal from trauma

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

Cancer drug shortages should be causing more outrage

The kidney, in all its complexity, is captured in a new atlas

Malaria cases in Florida and Texas: Here’s what you need to know

TikTok cracks down on users posting about weight loss drugs

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Lindsay Lohan welcomes 1st child with husband Bader Shammas

BioMarin wins approval for gene therapy to treat hemophilia A

FDA advisers vote against ALS treatment from BrainStorm

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

explore

After a drawn out lobbying fight, ARPA

'Reaching a detente': STAT's Helen Branswell on covering Covid

Address the ethical violations that led to 'Three Identical Strangers'

Did you have Obamacare on your GOP debate bingo card?

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

Stanford updates investigation of president’s past research

hotspot

hotspot

explore

hotspot